SANTA BARBARA, Calif., Nov. 01, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra”), a medical aesthetics company, today announced that it has granted a nonstatutory stock option under its Inducement Plan for 300,000 shares of Sientra common stock to Patrick F. Williams, Sientra’s new Chief Financial Officer, Senior Vice President, and Treasurer pursuant to the terms of his employment agreement with Sientra. This award was approved by the Compensation Committee of Sientra’s board of directors and was granted as an inducement material to Mr. Williams’ entering into employment with Sientra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Mr. Williams’ stock option was granted effective October 26, 2016 and has a ten year term and an exercise price equal to $7.93 per share, which was the closing trading price of Sientra’s common stock on the NASDAQ Global Select Market on the date of grant. Such stock option vests, as to 200,000 shares subject to the option, over the course of four years with 25% of the shares subject to the option vesting on the one-year anniversary of the grant date and 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter, and as to 100,000 shares subject to the option, in accordance with performance criteria established by the Compensation Committee. Vesting is subject to Mr. Williams’ continued service relationship with Sientra on each vesting date.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products including bioCorneum®, the professional choice in scar management.
Investor Contacts: Patrick F. Williams Sientra, Chief Financial Officer (619) 675-1047 [email protected] Nick Laudico / Brian Johnston The Ruth Group (646) 536-7030 / (646) 536-7028 [email protected]


noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 



